1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Sector news
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-08-10 am EDT
0.0260 AUD   +8.33%
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Sector news Other Biotechnology & Medical Research
08/09Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08/09European Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
MT
08/09Novavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
08/08Novavax sinks after halving sales forecast on low vaccine demand, supply glut
RE
08/08GlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
08/08INSIDER SELL : Moderna
MT
08/08INSIDER SELL : Moderna
MT
08/04Goldman Sachs Raises Moderna's Price Target to $296 From $290, Maintains Buy Rating
MT
08/04Morgan Stanley Adjusts Moderna's Price Target to $197 From $199, Maintains Equalweight ..
MT
08/04Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $225 From $159, Maintains..
MT
08/04SVB Securities Adjusts Moderna's Price Target to $74 from $77, Keeps Underperform Ratin..
MT
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Techno..
MS
08/04Needham Adjusts Price Target on Alnylam Pharmaceuticals to $240 From $205, Reiterates B..
MT
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
08/04Moderna Reiterates $21 Billion COVID-19 Vaccine Sales Forecast On Expected New Approval..
MT
08/03Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $225 From $159, Keeps..
MT
08/03Chardan Research Lifts Price Target on Alnylam Pharmaceuticals to $250 From $200 on Pat..
MT
08/03US Stocks Advance on Surprise Increase in Service Activity, Rise in Factory Orders
MT
08/03Nasdaq ends at three-month high as PayPal fuels optimism
RE
08/03Nasdaq ends at three-month high as PayPal fuels optimism
RE
08/03SECTOR UPDATE : Health Care Stocks Hanging on for Modest Gains
MT
08/03Nasdaq hits three-month high as PayPal fuels optimism
RE
08/03Top Midday Gainers
MT
08/03MIDDAY REPORT : US Stocks Rise With Treasury Yields After ISM Services Index Posts Surpris..
MT
08/03SECTOR UPDATE : Health Care Stocks Edging Higher This Afternoon
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03Earnings Flash (MRNA) MODERNA Posts Q2 Revenue $4.75B
MT
08/03Moderna Up Over 16%, on Pace for Largest Percent Increase Since November 2021 -- Data T..
DJ
08/03Moderna Reiterates Full-Year Vaccine Sales Outlook Despite Low COVAX Orders After Secon..
MT
08/03Alnylam Pharmaceuticals Meets Primary Endpoint in Phase 3 Clinical Trial of Patisiran; ..
MT
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
08/03SECTOR UPDATE : Health Care Stocks Advance Pre-Bell Wednesday
MT
08/03TRANSCRIPT : Alnylam Pharmaceuticals, Inc. - Special Call
CI
08/03TRANSCRIPT : Moderna, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03Stocks Signal Higher Session as US Futures Gain Pre-Bell; Asia Mostly Gains, Europe Adv..
MT
08/03Moderna Earnings Decline While Sales Increase in Q2; Adds $3 Billion Share Buyback
MT
08/03Wall Street Leans Forward Pre-Bell; Futures Green, Europe Up, Asia Higher
MT
08/03Moderna, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/03Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Pa..
CI
08/01Berenberg Bank Adjusts Seagen's Price Target to $183 From $180, Maintains Buy Rating
MT
08/01INSIDER SELL : Moderna
MT
08/01SVB Securities Adjusts Moderna's Price Target to $77 From $70, Maintains Underperform R..
MT
07/29INSIDER SELL : Moderna
MT
07/29INSIDER SELL : Moderna
MT
07/29IQVIA Holdings Inc. Announces Executive Changes
CI
07/29Stifel Nicolaus Adjusts Seagen Price Target to $170 From $145, Maintains Hold Rating
MT
07/29Morgan Stanley Lowers Alnylam Pharmaceuticals' Price Target to $159 From $164, Keeps Eq..
MT
07/29Morgan Stanley Raises Seagen's Price Target to $181 From $180, Maintains Overweight Rat..
MT
07/29Oppenheimer Adjusts Alnylam Pharmaceuticals' Price Target to $170 From $205, Maintains ..
MT
07/29SECTOR UPDATE : Consumer Stocks Mixed Premarket Friday
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on PATRYS LIMITED